January 4, 2026 – The Xihu District Technology Innovation Conference and the "296X" Advanced Manufacturing Cluster Promotion Meeting were held grandly at the Xihu District Cultural and Sports Center. This marks the third consecutive year that Xihu District has dedicated its "kick-off meeting" to the theme of technology innovation.

At the conference, Westlake Pharma was honored with two prestigious awards: Excellent Innovation and Entrepreneurship Team and Cutting-edge Innovation Rising Star.

Under the theme "Premier Xihu, New Quality Engine — Technology Innovation Leading High-Quality Development in Advanced Manufacturing," the conference was aligned with the overarching "114X" manufacturing goals and the "Two Highs and Two Zones" brand strategy. The event provided a comprehensive review of the 2025 achievements in science and technology, outlined a strategic path for future development, and issued a rallying call for the district to advance technology innovation to a new level while strengthening the "296X" advanced manufacturing cluster.

During the conference, the top ten technology events of Xihu District for 2025 were unveiled. The "Innovative Xihu" action plan and a new list of innovation scenario opportunities were released, and a series of high-quality projects were signed. Additionally, the district recognized outstanding enterprises for their 2025 performance. Westlake Pharma was awarded the title of Cutting-edge Innovation Rising Star and successfully retained its title as an Excellent Innovation and Entrepreneurship Team.

The event brought together distinguished experts and scholars from universities and research institutes, leadership from Xihu District government, and representatives from tech platforms, enterprises, and investment institutions.

In recent years, Xihu District has actively promoted the construction of an innovation ecosystem centered around local universities, successfully facilitating the translation of scientific and technological achievements from "the laboratory to the market."

As an enterprise incubated by Westlake University and Westlake Laboratory, Westlake Pharma bridges the academic and industrial sectors and is actively exploring efficient pathways for technology commercialization. The company's growth is inseparable from the support of high-level basic research, a robust tech-industry-finance ecosystem, and the consistent backing of the government.

The year 2026 marks the beginning of the "15th Five-Year Plan" and is a critical year for fully implementing new development philosophies and driving high-quality development. Standing at this new starting line, Westlake Pharma remains committed to the R&D of novel therapeutics. The company will further deepen the application of cutting-edge technologies in drug design, accelerate the clinical translation of scientific achievements, and continue to the Healthy China initiative.